NTWO OFF Achieved Positive Results of Over 22% improvement in Reduction of N2O Emissions in Open Greenhouse Environment
May 09, 2024 09:18 ET
|
N2OFF Inc.
Recent greenhouse study resulted in a reduction of emissions of up to 54% compared to a previous study reduction of up to 44% Neve Yarak, Israel, May 09, 2024 (GLOBE NEWSWIRE) -- N2OFF, Inc.\...
Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV)
January 30, 2024 01:00 ET
|
Hyloris Pharmaceuticals SA
Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV) Les deux groupes de...
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)
January 30, 2024 01:00 ET
|
Hyloris Pharmaceuticals SA
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and...
Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo
September 03, 2020 08:30 ET
|
Auris Medical AG
Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trialImprovement 1.9 to 2.4 times greater with highest dose than with placeboTrial to proceed with Part B to test AM-125...
Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
October 26, 2018 21:18 ET
|
Retrophin, Inc.
Increasing achievement of FSGS partial remission of proteinuria and stable eGFR observed out to 84 weeks in open-label extension Findings presented at ASN Kidney Week 2018 SAN DIEGO, Oct. 26,...